ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Decreased by Levin Capital Strategies L.P.

Levin Capital Strategies L.P. lowered its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 61.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,250 shares of the company's stock after selling 81,750 shares during the period. Levin Capital Strategies L.P. owned about 0.05% of ARS Pharmaceuticals worth $286,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in ARS Pharmaceuticals by 9.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 83,924 shares of the company's stock valued at $317,000 after purchasing an additional 7,024 shares during the period. Letko Brosseau & Associates Inc. acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at approximately $136,000. RA Capital Management L.P. raised its holdings in shares of ARS Pharmaceuticals by 214.3% during the third quarter. RA Capital Management L.P. now owns 9,459,678 shares of the company's stock valued at $35,758,000 after buying an additional 6,450,000 shares during the last quarter. Denali Advisors LLC bought a new position in ARS Pharmaceuticals in the 4th quarter worth approximately $480,000. Finally, China Universal Asset Management Co. Ltd. increased its position in ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company's stock valued at $61,000 after acquiring an additional 8,652 shares during the period. 68.16% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. purchased 505,954 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The stock was acquired at an average price of $9.79 per share, for a total transaction of $4,953,289.66. Following the transaction, the director now owns 9,958,073 shares in the company, valued at $97,489,534.67. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Ra Capital Management, L.P. bought 505,954 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were acquired at an average cost of $9.79 per share, for a total transaction of $4,953,289.66. Following the purchase, the director now owns 9,958,073 shares of the company's stock, valued at approximately $97,489,534.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $9.02, for a total transaction of $890,977.56. Following the completion of the transaction, the insider now owns 1,747,294 shares in the company, valued at approximately $15,760,591.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 503,260 shares of company stock worth $4,612,480. Company insiders own 35.60% of the company's stock.

ARS Pharmaceuticals Stock Up 3.1 %

ARS Pharmaceuticals stock traded up $0.29 during mid-day trading on Friday, hitting $9.75. The company's stock had a trading volume of 364,083 shares, compared to its average volume of 606,480. The stock has a market capitalization of $944.68 million, a P/E ratio of -17.11 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a twelve month low of $2.55 and a twelve month high of $11.27. The stock's fifty day moving average price is $8.99 and its two-hundred day moving average price is $6.57.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.07. Equities analysts expect that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SPRY shares. SVB Leerink raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $6.00 to $18.00 in a report on Tuesday, March 5th. Wedbush restated an "outperform" rating and issued a $19.00 target price on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Leerink Partnrs raised ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 5th. Finally, William Blair raised ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a report on Tuesday, February 20th.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.